List Price Increase 'Incentives' Must Be Reversed, HHS Nominee Azar Says
Senate Finance Committee Democrats grill HHS Secretary nominee Alex Azar about his ability to foster solutions to high drug pricing given his industry background, as well as his support for alternative financing in Medicaid.
You may also be interested in...
During the first step of the confirmation process, HHS Secretary nominee Alex Azar did a good job of framing his industry background as useful experience for tackling drug prices. But wouldn’t it be nice if everyone agreed that 10 years as Lilly was something to be proud of?
Alex Azar talks about price negotiation in Medicare Part B, whether his biopharma industry ties would influence his decisions as head of HHS, insulin price increases and importation during the first of his confirmation hearings.
Price increases generated 100% of net US earnings growth at major biopharma firms in 2016, according to investment analyst report assessing threat of continued pricing pressure.